John Charles Rademacher Purchases 12,500 Shares of Option Care Health (NASDAQ:OPCH) Stock

Option Care Health, Inc. (NASDAQ:OPCH) CEO John Charles Rademacher purchased 12,500 shares of the company’s stock in a transaction dated Monday, May 4th. The shares were purchased at an average cost of $21.18 per share, for a total transaction of $264,750.00. Following the transaction, the chief executive officer directly owned 695,152 shares in the company, valued at approximately $14,723,319.36. The trade was a 1.83% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website.

Option Care Health Stock Up 0.8%

OPCH stock opened at $21.30 on Wednesday. The stock has a fifty day moving average of $28.86 and a 200-day moving average of $30.70. Option Care Health, Inc. has a fifty-two week low of $18.01 and a fifty-two week high of $36.80. The company has a market capitalization of $3.34 billion, a price-to-earnings ratio of 16.51, a PEG ratio of 1.21 and a beta of 0.68. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.07 and a current ratio of 1.64.

Option Care Health (NASDAQ:OPCH) last announced its quarterly earnings data on Thursday, April 30th. The company reported $0.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.03. The business had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.39 billion. Option Care Health had a return on equity of 18.17% and a net margin of 3.64%.The firm’s quarterly revenue was up 1.3% compared to the same quarter last year. During the same period in the previous year, the business posted $0.40 EPS. Option Care Health has set its FY 2026 guidance at 1.820-1.920 EPS. As a group, equities research analysts predict that Option Care Health, Inc. will post 1.69 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. V Square Quantitative Management LLC purchased a new position in Option Care Health during the fourth quarter worth about $25,000. Cornerstone Planning Group LLC raised its holdings in shares of Option Care Health by 7,621.4% in the 3rd quarter. Cornerstone Planning Group LLC now owns 1,081 shares of the company’s stock valued at $30,000 after acquiring an additional 1,067 shares in the last quarter. Advisory Services Network LLC bought a new stake in shares of Option Care Health during the 3rd quarter valued at about $35,000. McIlrath & Eck LLC bought a new stake in shares of Option Care Health during the 2nd quarter valued at about $37,000. Finally, Caitong International Asset Management Co. Ltd purchased a new position in shares of Option Care Health during the third quarter worth about $38,000. Institutional investors own 98.05% of the company’s stock.

Trending Headlines about Option Care Health

Here are the key news stories impacting Option Care Health this week:

• Positive Sentiment: Large insider buys: CEO John Rademacher purchased 12,500 shares (~$21.18 avg) and Director Harry M. Jansen Kraemer Jr. bought 36,610 shares (~$21.41 avg), increasing their stakes — a strong signal of management confidence that often supports the stock. CEO SEC Filing Director SEC Filing
• Neutral Sentiment: JPMorgan lowered its price target from $40 to $33 but kept an “overweight” rating — the cut reduces upside expectations but the continued overweight endorsement still lends institutional support. JPMorgan Coverage
• Neutral Sentiment: Chief Growth Officer transition announced (Christopher Grashoff departing) — management changes can be routine but may prompt questions about near‑term business execution until a successor is named. CGO Transition
• Neutral Sentiment: Participation in the Bank of America Health Care Conference (May 12) gives management a platform to update investors — can be a catalyst if new guidance or strategic detail is provided. Conference Notice
• Neutral Sentiment: Recent Q1 results: EPS beat ($0.40 vs. $0.37) but revenue slightly missed; FY‑2026 EPS guidance set at $1.82–$1.92 — mixed fundamentals that leave upside tied to margin improvement and execution. Earnings & Guidance
• Negative Sentiment: Securities‑fraud investigation: law firm Block & Leviton is investigating OPCH for potential securities claims — this raises legal/ reputational risk and could pressure the stock if litigation or regulatory action follows. Investigation Alert

Wall Street Analysts Forecast Growth

OPCH has been the subject of a number of recent research reports. Citigroup reiterated an “outperform” rating on shares of Option Care Health in a research note on Tuesday, January 13th. Bank of America lowered Option Care Health from a “buy” rating to a “neutral” rating and set a $22.00 price target for the company. in a report on Friday, May 1st. National Bank Financial set a $37.00 price objective on Option Care Health in a research note on Tuesday, January 27th. Wall Street Zen cut Option Care Health from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Finally, Citizens Jmp reaffirmed a “market outperform” rating and set a $38.00 target price (up from $36.00) on shares of Option Care Health in a report on Tuesday, January 13th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, Option Care Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.08.

About Option Care Health

Option Care Health (NASDAQ: OPCH) is a leading provider of home and alternate site infusion services in the United States. The company specializes in the administration of injectable therapies, including antibiotics, nutrition, hydration, immunoglobulin, pain management and specialty pharmaceuticals. Through its nationwide network of infusion pharmacies and nursing professionals, Option Care Health delivers customized care plans and in-home nursing visits to patients managing complex or chronic conditions outside of a hospital setting.

Option Care Health traces its current structure to the completion of its merger with BioScrip in early 2021, combining two of the industry’s most experienced home infusion businesses.